200006059-0 ; IPOS-Ref.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 215/56, A61K 31/47 — A1

(11) International Publication Number: WO 99/55678

(43) International Publication Date: 4 November 1999 (04.11.99)

(21) International Application Number: PCT/SE99/00676

(22) International Filing Date: 26 April 1999 (26.04.99)

(30) Priority Data:
9801474-9 27 April 1998 (27.04.98) SE

(71) Applicant: ACTIVE BIOTECH AB [SE/SE]; P.O. Box 724, S–220 07 Lund (SE).

(72) Inventors: BJÖRK, Anders; Svalvägen 9, S–237 36 Bjärred (SE). JÖNSSON, Stig; Sofiaparken 2, S–222 41 Lund (SE). SFEX, Tomas; Harpasset 1, S–226 52 Lund (SE). HEDLUND, Gunnar; Gullregnsvägen 131 E, S–224 56 Lund (SE).

(74) Agents: BERGVALL EFTRING, Stina, Lena et al.; Dr. Ludwig Brann Patentbyrå AB, P.O. Box 17192, S–104 62 Stockholm (SE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

1 PD,
1 appl'n
4 Invs. (1st = symbol "0"
2nd = symbol "1")

(54) Title: QUINOLINE DERIVATIVES



IPC : C07D 215/56
A61K 31/47
(1) IPER 9/11/99

(57) Abstract

The invention relates to compounds of general formula (I) wherein R is selected from ethyl, n–propyl, iso–propyl, n–butyl, iso–butyl, sec.–butyl and allyl; R_4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R_5 is selected from methyl, ethyl, n–propyl, iso–propyl, methoxy, ethoxy, chloro, bromo, CF_3, and OCH_xF_y; wherein $x = 0 - 2$, $y = 1 - 3$ with the proviso that $x + y = 3$; R_6 is hydrogen; or R_5 and R_6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods of treating mammals suffering from diseases resulting from autommunity and pathological inflammation by administrering a compound having formula (I) to said mammal.